Skip Navigation


NDT Advance Access originally published online on February 20, 2006
Nephrology Dialysis Transplantation 2006 21(6):1626-1632; doi:10.1093/ndt/gfl034
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
21/6/1626    most recent
gfl034v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Albalate, M.
Right arrow Articles by Caramelo, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Albalate, M.
Right arrow Articles by Caramelo, C.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2006]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org


Original Articles: Dialysis and Transplantation

Association between phosphate removal and markers of bone turnover in haemodialysis patients

Marta Albalate1, Concepción de la Piedra2, Cristina Fernández3, Mar Lefort2, Henar Santana1, Paloma Hernando1, Jesús Hernández1 and Carlos Caramelo2

1 Fundación Renal Iñigo Álvarez de Toledo, Instituto Reina Sofía de Investigación Nefrológica, 2 Servicios de Nefrología and Bioquímica, Fundación Jiménez Díaz and 3 Servicio de Epidemiología, Hospital Clínico, Universidad Autónoma and Universidad Complutense, Madrid, Spain

Correspondence and offprint requests to: Dr Carlos Caramelo, Laboratorio de Nefrología-Hipertensión, Fundación Jiménez Díaz, Universidad Autónoma, Avda. Reyes Católicos 2, 28040 Madrid, Spain. Email: ccaramelo{at}fjd.es

Background. As the main mineral reservoir, bone acts as a calcium (Ca) and phosphate buffering system. Accordingly, phosphate removal by haemodialysis (HD) might be theoretically influenced by bone turnover, as well as by the interaction of regulatory molecules, such as PTH and osteoprotegerin (OPG). The present study investigated the relationship between these variables and phosphate removal by HD.

Methods. Blood samples for serum Ca, phosphate, bicarbonate, intact PTH, PTH (1–84), bone alkaline phosphatase, tartrate-resistant acid phosphatase 5b, OPG and receptor activator of nuclear factor-{kappa}B ligand (RANKL) were obtained in 28 HD patients. Phosphate removal was measured by a continuous collection of the dialysate.

Results. Pre-dialysis serum phosphate concentration is the critical factor in determining dialytic phosphate removal. However, multiple regression analysis reveals that phosphate removal is better explained by a combination of factors than by phosphate concentration alone. In this model, the PTH/OPG ratio is an additional positive factor, whereas age and vitamin D treatment are negative factors. Patients with pre-HD bicarbonate higher than 20 mEq/l had higher serum phosphate and, accordingly, higher phosphate removal; of interest, these individuals also have significant differences in RANKL/OPG. Mean (SD) OPG levels were significantly higher than that in the healthy population (16.2 (12.5) pmol/l; these values correlated with age (r = 0.4, P<0.04). Mean serum RANKL (1.03 (1.02) pmol/l) was within the range of normal individuals.

Conclusions. Dialytic phosphate removal has a crucial, direct relationship with pre-HD plasma phosphate levels. However, the phenomenon of phosphate removal is more precisely explained using a more complex relationship, defined by the interaction between serum phosphate, PTH/OPG, age and vitamin D administration. Serum RANKL levels are first reported in HD patients, and are not different from the normal population.

Keywords: Bone turnover; haemodialysis; osteoprotegerin; phosphate removal; PTH; RANKL


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Nephrol Dial TransplantHome page
J. Punal, L. V. Lema, D. Sanhez-Guisande, and A. Ruano-Ravina
Clinical effectiveness and quality of life of conventional haemodialysis versus short daily haemodialysis: a systematic review
Nephrol. Dial. Transplant., August 1, 2008; 23(8): 2634 - 2646.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
A. E. Grzegorzewska
Markers of bone turnover in haemodialysis patients
Nephrol. Dial. Transplant., December 1, 2006; 21(12): 3602 - 3603.
[Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
S. G. Achinger and J. C. Ayus
Left Ventricular Hypertrophy: Is Hyperphosphatemia among Dialysis Patients a Risk Factor?
J. Am. Soc. Nephrol., December 1, 2006; 17(12_suppl_3): S255 - S261.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.